DiaMedica Inc. Announces Results of Annual General and Special Meeting
December 20 2013 - 5:50PM
Marketwired
DiaMedica Inc. Announces Results of Annual General and Special
Meeting
MINNEAPOLIS, MINNESOTA--(Marketwired - Dec 20, 2013) - DiaMedica
Inc. (TSX-VENTURE:DMA), a biotechnology company focused on
diabetes, is pleased to announce that at the Annual General and
Special Meeting (the "Meeting") of shareholders of DiaMedica held
on December 16, 2013, Michael Giuffre, Rick Pauls, Dawson Reimer,
Richard Pilnik and Thomas Wellner were re-elected as the board of
directors of DiaMedica.
In addition to the election of directors, the shareholders
passed all resolutions placed before the Meeting as outlined in the
management information circular dated November 6, 2013, including
re-appointment of KPMG LLP, Chartered Accountants, as auditors for
the upcoming year and authorizing the board of directors of
DiaMedica at its discretion to amend the Articles of Incorporation
of DiaMedica to consolidate the outstanding common shares of
DiaMedica at a future date on the basis of one pre-consolidation
common share for each two to five post-consolidation common share
as more particularly described in the management information
circular.
About DiaMedica
DiaMedica Inc.
(TSX-VENTURE:DMA) is a biotechnology company developing
first-in-class treatments for the treatment of diabetes.
DiaMedica's lead compound, DM199, is a recombinant human protein
for the treatment of both Type 1 and Type 2 diabetes and their
complications. The Company is also developing the first therapeutic
GPCR agonist monoclonal antibody, DM204, for the treatment of Type
2 diabetes and cardiovascular disease. DiaMedica's shares trade on
the TSX Venture Exchange (TSX-VENTURE:DMA). For more information
please visit www.diamedica.com.
FORWARD-LOOKING STATEMENTS
The statements made in this
press release that are not historical facts contain forward-looking
information that involves risk and uncertainties. All statements,
other than statements of historical facts, which address
DiaMedica's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of
business judgment as well as assumptions made by and information
currently available to management. When used in this document, the
words "may", "will", "anticipate", "believe", "estimate", "expect",
"intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on
these forward-looking statements. These statements reflect a
current view of future events and are subject to certain risks and
uncertainties as contained in the Company's filings with Canadian
securities regulatory authorities. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially
from those anticipated in these forward-looking statements. The
Company undertakes no obligation, and does not intend, to update,
revise or otherwise publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof, or to reflect the occurrence of any unanticipated
events. Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these
expectations will materialize.
Neither the TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of the contents of this
News Release.
DiaMedicaRick PaulsPresident and
CEO763-710-4455info@diamedica.comDiaMedicaOne Carlson Parkway,
Suite 124Minneapolis, MNwww.diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024